Letters to the Editor

ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Haematologica Early view Jun 20, 2024 https://doi.org/10.3324/haematol.2024.285410